In our study, we examined the therapeutic effects of a synthesis of technologies that work in concert to optimize a drug delivery system using a third-generation oncolytic virus to target an in vivo TNBC xenograft model in humanized mice (Hu-CD34+ NSG-SGM3) with or without checkpoint inhibitor combination therapy to understand the role of ultrasound-targeted destruction of MB/OV complexes on the immune system and its therapeutic impact on the recruitment of CD4+ and CD8+ TILs causing tumor clearance. Here, CD34 is linked to neoplasm.